Foothills Medical Centre
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Established
- 1966-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 4
1 (100.0%)Can Ultrasound Replace Computed Tomography (CT) Scan in Those Unable to Have Computed Tomography (CT) Contrast Agents
Completed
- Conditions
- Nephrotoxicity of CT Contrast AgentsCT Scans in Those With Renal CompromiseSensitivity to CT Contrast AgentsUS With CEUS as Replacement for Unenhanced CT Scan
- First Posted Date
- 2010-06-28
- Last Posted Date
- 2014-03-13
- Lead Sponsor
- Foothills Medical Centre
- Target Recruit Count
- 250
- Registration Number
- NCT01151566
- Locations
- 🇨🇦
Diagnostic Imaging Foothills Medical Centre, Calgary, Alberta, Canada
Contrast Enhanced (CE) Ultrasound and CE Computed Tomography or CE Magnetic Resonance Imaging in Liver Masses
Completed
- Conditions
- Liver Tumors
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Foothills Medical Centre
- Target Recruit Count
- 250
- Registration Number
- NCT00828607
- Locations
- 🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada
🇨🇦London Health Sciences Centre, University Hospital, London, Ontario, Canada
🇨🇦Sunnybrook Medical centre, Toronto, Ontario, Canada
Patient Reported Outcomes in Renal Transplant Patients Tolerating Gastrointestinal (GI) Symptoms Converted to Myfortic (EC-MPS)
Phase 4
- Conditions
- Kidney Transplant
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2008-05-15
- Lead Sponsor
- Foothills Medical Centre
- Target Recruit Count
- 110
- Registration Number
- NCT00676221
- Locations
- 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
News
Breakthrough Gene Therapy Eliminates Need for Enzyme Replacement in Fabry Disease Patients
Canadian researchers have successfully developed a one-time gene therapy treatment for Fabry disease that restored enzyme production to near-normal levels in all five trial participants within one week.